[go: up one dir, main page]

DE69837170D1 - Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen - Google Patents

Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen

Info

Publication number
DE69837170D1
DE69837170D1 DE69837170T DE69837170T DE69837170D1 DE 69837170 D1 DE69837170 D1 DE 69837170D1 DE 69837170 T DE69837170 T DE 69837170T DE 69837170 T DE69837170 T DE 69837170T DE 69837170 D1 DE69837170 D1 DE 69837170D1
Authority
DE
Germany
Prior art keywords
unprotected
cysteine
solid
aqueous solutions
chemical ligation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69837170T
Other languages
English (en)
Other versions
DE69837170T2 (de
Inventor
Lynne Canne
Stephen B H Kent
Reyna Simon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Original Assignee
Gryphon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gryphon Therapeutics Inc filed Critical Gryphon Therapeutics Inc
Publication of DE69837170D1 publication Critical patent/DE69837170D1/de
Application granted granted Critical
Publication of DE69837170T2 publication Critical patent/DE69837170T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
    • C07K1/086—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents containing sulfur
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/023—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution using racemisation inhibiting agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/026—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution by fragment condensation in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
DE69837170T 1997-06-13 1998-06-12 Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen Expired - Fee Related DE69837170T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4955397P 1997-06-13 1997-06-13
US49553P 1997-06-13

Publications (2)

Publication Number Publication Date
DE69837170D1 true DE69837170D1 (de) 2007-04-05
DE69837170T2 DE69837170T2 (de) 2007-11-22

Family

ID=21960431

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69837170T Expired - Fee Related DE69837170T2 (de) 1997-06-13 1998-06-12 Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen
DE69828287T Expired - Fee Related DE69828287T2 (de) 1997-06-13 1998-06-12 Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69828287T Expired - Fee Related DE69828287T2 (de) 1997-06-13 1998-06-12 Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen

Country Status (9)

Country Link
US (4) US6326468B1 (de)
EP (1) EP1001968B1 (de)
JP (1) JP2002505672A (de)
AT (2) ATE285415T1 (de)
AU (1) AU745094B2 (de)
CA (1) CA2292724A1 (de)
DE (2) DE69837170T2 (de)
ES (2) ES2282788T3 (de)
WO (1) WO1998056807A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184344B1 (en) * 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US6849428B1 (en) * 1997-03-05 2005-02-01 New England Biolabs, Inc. Intein-mediated protein ligation of expressed proteins
WO1998056807A1 (en) * 1997-06-13 1998-12-17 Gryphon Sciences Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution
CA2301846A1 (en) * 1997-09-04 1999-03-11 Gryphon Sciences Modular protein libraries and methods of preparation
AUPP589598A0 (en) 1998-09-14 1998-10-08 University Of Queensland, The Novel peptides
US7001745B1 (en) * 1998-09-30 2006-02-21 New England Biolabs, Inc. Intein mediated peptide ligation
JP2002539136A (ja) * 1999-03-11 2002-11-19 グリフォン サイエンシーズ 可溶性膜タンパク質受容体ドメイン類の化学合成と使用
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AU2001284853A1 (en) * 2000-08-11 2002-02-25 Invitrogen Corporation Highly homogeneous molecular markers for electrophoresis
US20040014082A1 (en) * 2000-08-11 2004-01-22 Invitrogen Corporation Highly homogeneous molecular markers for electrophoresis
MXPA03001449A (es) * 2000-09-01 2004-12-13 Gryphon Therapeutics Inc Compuestos generadores de tioester estables a nucleofilos, metodos para su produccion y su uso.
US7273923B2 (en) * 2001-01-22 2007-09-25 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
CA2439750A1 (en) * 2001-03-09 2002-09-19 Boston Probes, Inc. Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation
GB0113657D0 (en) * 2001-06-05 2001-07-25 Geneprot Inc Improved native chemical ligation with three or more components
CN105131104B (zh) 2001-10-10 2018-11-16 诺和诺德公司 肽的重构和糖缀合
DE60331437D1 (de) * 2002-06-10 2010-04-08 Amylin Pharmaceuticals Inc Nachspaltige sulfurentschützung zur konvergenten proteinherstellung beim verfahren von chemischer ligation
ES2254725T3 (es) * 2002-06-29 2006-06-16 Aquanova German Solubilisate Technologies (Agt) Gmbh Concentrados de isoflavonas y metodos para su preparacion.
US7598224B2 (en) * 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
US8227411B2 (en) 2002-08-20 2012-07-24 BioSurface Engineering Technologies, Incle FGF growth factor analogs
US7166574B2 (en) * 2002-08-20 2007-01-23 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
WO2004053460A2 (en) * 2002-12-11 2004-06-24 New England Biolabs, Inc. Carrier-ligand fusions and uses thereof
WO2004061094A1 (en) 2002-12-30 2004-07-22 Gryphon Therapeutics, Inc. Water-soluble thioester and selenoester compounds and methods for making and using the same
EP2338333B1 (de) 2003-04-09 2017-09-06 ratiopharm GmbH Glycopegylierungsverfahren und durch die Verfahren hergestellte Proteine/Peptide
SI2077121T1 (sl) * 2003-05-06 2011-07-29 Syntonix Pharmaceuticals Inc Strjevalni faktor VII-Fc himerni proteini za zdravljenje hemostatske motnje
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP1631597A4 (de) * 2003-05-22 2007-07-11 Gryphon Therapeutics Inc Chemische festphasenligation mit austauschbarem linker
US7414028B1 (en) * 2004-02-04 2008-08-19 Biosurface Engineering Technologies, Inc. Growth factor analogs
US20080227696A1 (en) 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
US20060024347A1 (en) * 2004-02-10 2006-02-02 Biosurface Engineering Technologies, Inc. Bioactive peptide coatings
US7528105B1 (en) 2004-02-10 2009-05-05 Biosurface Engineering Technologies Heterodimeric chain synthetic heparin-binding growth factor analogs
US7671012B2 (en) 2004-02-10 2010-03-02 Biosurface Engineering Technologies, Inc. Formulations and methods for delivery of growth factor analogs
JP4895826B2 (ja) 2004-02-20 2012-03-14 バイオサーフェス エンジニアリング テクノロジーズ，インク． 骨形成蛋白−２の正のモジュレーター
JP4823894B2 (ja) 2004-04-09 2011-11-24 中外製薬株式会社 新規水溶性プロドラッグ
WO2005115433A2 (en) * 2004-05-24 2005-12-08 Rigel Pharmaceuticals, Inc. Methods for cyclizing synthetic polymers
BRPI0609595A8 (pt) 2005-03-31 2018-05-15 Amylin Pharmaceuticals Inc composições e métodos para o controle, prevenção e tratamento da obesidade e desordens alimentares
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
WO2007100358A2 (en) * 2005-10-07 2007-09-07 University Of Chicago Convergent synthesis of proteins by kinetically controlled ligation
CA2626330A1 (en) * 2005-10-19 2007-04-26 Chugai Seiyaku Kabushiki Kaisha Preventive or therapeutic agents for pancreatic cancer, ovarian cancer, or liver cancer comprising a novel water-solube prodrug
US7820172B1 (en) 2006-06-01 2010-10-26 Biosurface Engineering Technologies, Inc. Laminin-derived multi-domain peptides
WO2007150053A2 (en) 2006-06-22 2007-12-27 Biosurface Engineering Technologies, Inc. Composition and method for delivery of bmp-2 amplifier/co-activator for enhancement of osteogenesis
WO2008097536A2 (en) 2007-02-05 2008-08-14 Amylin Pharmaceuticals, Inc. Compositions and methods for treating psychiatric diseases and disorders
WO2009032133A2 (en) * 2007-08-28 2009-03-12 Ipsen Pharma S.A.S. Methods and intermediates for chemical synthesis of polypeptides and proteins
WO2011103409A1 (en) * 2010-02-18 2011-08-25 Advanced Proteome Therapeutics Inc. Site-specific modification of proteins through chemical modification enabling protein conjugates, protein dimer formation, and stapled peptides
EP2621538B1 (de) 2010-09-28 2015-12-16 Amylin Pharmaceuticals, LLC Manipulierte polypeptide mit verlängerter wirkungsdauer
PT2621515T (pt) 2010-09-28 2017-07-12 Aegerion Pharmaceuticals Inc Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada
US9382304B2 (en) 2011-07-08 2016-07-05 Amylin Pharmaceuticals, Llc Engineered polypeptides having enhanced duration of action with reduced immunogenicity
CN103957926B (zh) 2011-07-08 2018-07-03 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
FR2981352B1 (fr) * 2011-10-17 2015-07-03 Centre Nat Rech Scient Procede de synthese de proteines
EP2850201A4 (de) 2012-05-11 2016-08-31 Alexander Krantz Ortsspezifische markierung und gezielte verabreichung von proteinen zur behandlung von krebs
US9731029B2 (en) 2012-05-21 2017-08-15 Massachusetts Institute Of Technology Protein retrosplicing enabled by a double ligation reaction
JP6387392B2 (ja) 2013-03-15 2018-09-05 バイオベラティブ セラピューティクス インコーポレイテッド 第ｉｘ因子ポリペプチド製剤
WO2017151939A1 (en) * 2016-03-02 2017-09-08 The Brigham And Women's Hospital, Inc. Use of pla2g5-deficient suppressive macrophages in suppression of inflammation
AU2018228182B2 (en) * 2017-03-02 2024-04-11 Glytech, Inc. Production method for amino-acid polymer
KR20210072021A (ko) 2018-10-01 2021-06-16 유니베르시떼 드 제네브 생물학 분석에 적합한 복수의 폴리펩티드 변이체의 생산 방법
JP7281826B2 (ja) * 2018-11-30 2023-05-26 株式会社糖鎖工学研究所 ペプチドチオエステル、ペプチドの新規製造方法
EP4041310A4 (de) 2019-10-10 2024-05-15 1859, Inc. Methoden und systeme für mikrofluidisches screening
CN110945009B (zh) * 2019-10-23 2023-10-31 烟台迈百瑞国际生物医药股份有限公司 一种寡肽连接子中间体及其制备方法
WO2022266467A2 (en) 2021-06-17 2022-12-22 Dana-Farber Cancer Institute, Inc. Recombinant histone polypeptide and uses thereof
WO2024146707A1 (en) 2023-01-06 2024-07-11 Université De Genève Variant ligand conjugates for payload delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064940A (en) * 1988-05-11 1991-11-12 Protein Technologies, Inc. Premixed dry reagent containing a protected amino acid and an activating agent for use in solid phase protein synthesis
US5101059A (en) * 1989-12-05 1992-03-31 Research Corporation Technologies, Inc. Amino acid protecting groups
JP3599346B2 (ja) 1995-05-04 2004-12-08 ザ スクリップス リサーチ インスティチュート 天然型化学連結反応によるタンパク質の合成
JP4358307B2 (ja) * 1996-12-24 2009-11-04 ザ スクリップス リサーチ インスティテュート 一般的化学結合
WO1998056807A1 (en) * 1997-06-13 1998-12-17 Gryphon Sciences Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution
US6329468B1 (en) * 2000-01-21 2001-12-11 Bostik Findley, Inc. Hot melt adhesive based on semicrystalline flexible polyolefins

Also Published As

Publication number Publication date
US7030217B2 (en) 2006-04-18
AU8069598A (en) 1998-12-30
ATE354584T1 (de) 2007-03-15
WO1998056807A1 (en) 1998-12-17
US20050209440A1 (en) 2005-09-22
US7094871B2 (en) 2006-08-22
EP1001968B1 (de) 2004-12-22
DE69828287D1 (de) 2005-01-27
US20020132975A1 (en) 2002-09-19
JP2002505672A (ja) 2002-02-19
US6326468B1 (en) 2001-12-04
ATE285415T1 (de) 2005-01-15
EP1001968A1 (de) 2000-05-24
US20020169282A1 (en) 2002-11-14
ES2235336T3 (es) 2005-07-01
CA2292724A1 (en) 1998-12-17
DE69837170T2 (de) 2007-11-22
DE69828287T2 (de) 2005-12-15
ES2282788T3 (es) 2007-10-16
AU745094B2 (en) 2002-03-14

Similar Documents

Publication Publication Date Title
DE69837170D1 (de) Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen
Tsaprailis et al. Influence of secondary structure on the fragmentation of protonated peptides
Dongré et al. Influence of peptide composition, gas-phase basicity, and chemical modification on fragmentation efficiency: evidence for the mobile proton model
Han et al. Ion trap collisional activation of c and z• ions formed via gas-phase ion/ion electron-transfer dissociation
NO993341L (no) Analoger av paratyroidhormon
NZ527053A (en) Modified amyloid precursor protein polynucleotides and polypeptides
WO2003057845A3 (en) Automated systems and methods for analysis of protein post-translational modification
DE69703449D1 (de) Neuroaktive peptide
GB2330450B (en) Chemical ionization source for mass spectrometry
AU4052389A (en) Derivatized glass supports for peptide and protein sequencing
WO2003074992A3 (en) Phosphorylated proteins and uses related thereto
EP0699753A3 (de) Transportprotein, das den Transport von kationischen Xenobiotika und/oder Pharmaka bewirkt, dafür kodierende DNA-Sequenzen und deren Verwendung
GB9816514D0 (en) Novel method
WO2004018644A3 (en) HETEROGENEOUS FOLDAMERS CONTAINING α, β, AND/OR Ϝ-AMINO ACIDS
AUPR378001A0 (en) Protein chip
Wanigasekara et al. Evaluation of chemical labeling methods for identifying functional arginine residues of proteins by mass spectrometry
Moyer et al. Fragmentation of cationized phosphotyrosine containing peptides by atmospheric pressure MALDI/Ion trap mass spectrometry
WO2002037121A3 (en) Detection of modified amino acids by mass spectrometry
AU2002322506A1 (en) Non-affinity based isotope tagged peptides and methods for using the same
Baker et al. Tandem mass spectrometry of model peptides modified with trans-2-hexenal, a product of lipid peroxidation
NO982227D0 (no) Urogenitalcarcinom-TPL komplekspeptider og antistoffer derav
WO2003087805A3 (en) Method for efficiently computing the mass of modified peptides for mass spectrometry data-based identification
EP1518862A3 (de) Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen
DE59801808D1 (de) Verfahren zur vermittlung von transaktionsschritten

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: AMYLIN PHARMACEUTICALS, INC., SAN DIEGO, CALIF, US

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee